54. Roehrborn CG, Bruskewitz R, Nickel GC, Glickman S, Cox C, Anderson R, Kandzari S, Herlihy R, Kornitzer G, Brown BT, Holtgrewe HL, Taylor A, Wang D, Waldstreicher J for the PLESS Study Group. Eur Urol, 2000: 37, 528-536 55. Bruskewitz R, Girman CJ, Fowler J, Rigby OF, Sullivan M, Bracken RB, Fusilier HA, Kozlowsky D, Kantor SD, Johnson EL, Wang DZ and Waldstreicher J for the PLESS Study Group. Effect of finasteride on bother and other health-related quality of life aspects associated with benign prostatic hyperplasia. Urology, 1999: 54, 670-678 56. Wessels H, Roy J, Bannow J, Grayhack J, Matsumoto AM, Tenover L, Herlihi R, Fitch W, Labasky R, Auerbach S, Parra R, Rajfer J, Culbertson J, Lee M, Bach MA and Waldstreicher J for the PLESS Study Group. Incidence and severity of sexual adverse experiences in finasteride and placebo-treated men with benign prostatic hyperplasia. Urology, 2003: 61, 579-584 57. Lowe FC, McConnell JD, Hudson PB, Romas NA, Boake R, Lieber M, Elhilali M, Geller J, Imperato-McGinley J, Andriole GL, Bruskewitz RC, Walsh PC, Bartsch G, Nacey JN, Shah S, Pappas F, Ko A, Cook T, Stoner E and Waldstreicher J, for the Finasteride Study Group. Long -term 6-year experience with Finasteride in patients with benign prostatic hyperplasia. Urology, 2003: 61, 791-796 58. Thompson IM, Goodman PJ, Tangen CM, Scott Lucia M, Miller GJ, Ford LG, Lieber MM, Cespedes D, Atkins JN, Lippman SM, Carlin SM, Ryan A, Szczepanek CM, Crowley JJ, Coltman CA. The influence of Finasteride on the development of prostate cancer. N Engl J Med, 2003: 349, 215-224 59. Roehrborn CG, Boyle P, Nickel JC, Hoefner K and Andriole G, on behalf of the ARIA3001, ARIA3002, and ARIA3003 STUDY INVESTIGATORS. Efficacy and safety of a dula inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology, 2002: 60, 434-441 60. Andriole GL, Kirby R. Safety and tolarability of the dual 5alpha-reductase inhibitor Dutasteride in the treatment of benign prostatic hyperplasia. Eur Urol, 2003: 44, 82- 88 61. Mebust WK, Holtgrewe HL, Cockett AT, Peters PC. Transurethral prostatectomy: immediate and postoperative complications. A cooperative study of 13 participating institutions evaluating 3885 patients. J Urol, 1989: 141, 243-247 62. Wasson JH, Reda DJ, Bruskewitz RC, Elinson J, Keller AM, Henderson WG. A comparison of transurethral surgery with watchful waitng for moderate symptoms of benign prostatic hyperplasia: The Veteran Affairs Cooperative Study Group on Transurethral Resection of the Prostate. N Engl J Med, 1995: 332, 75-79 63. Soderdahl DW, Knight RW and Hansberry KL. Erectile dysfunction following transurethral resection of the prostate. J Urol, 1996: 156, 1354-1360 64. Gilling PJ, Mackey M, Cresswell M, Kennett K, Kabalin JN and Fraundorfer MR. Holmium laser versus transurethral resection of the prostate: a randomized prospective trial with 1-year followup. J Urol, 1999: 162, 1640-1644 65. Arai Y, Aoki Y, Okubo K, Maeda H, Terada N, Matsuta Y, Maekawa S and Ogura K. Impact of interventional therapy for benign prostatic hyperplasia on quality of life and sexual function: a prospective study. J Urol, 2000: 164, 1206-1211 249
66. Leliefeld HHJ, Stoevelaar HJ and Mc Donnell J. Sexual function before and after various treatments for symptomatic benign prostatic hyperplasia. BJU Int, 2002: 89, 208-213 67. Donovan JL, Peters TJ, Neal DE, Brookes ST, Gujral S, Chacko KN, Wright M, Kennedy LG an Abrams P. A randomized trial comparing transurethral resection of the prostate, laser therapy and conmservative treatment of men with symptoms associated with benign prostatic enlargement: the ClasP Study. J Urol, 2000: 164, 65-70 68. Brookes ST, Donovan JL, Peters TJ, Abrams P, Neal DE. Sexual dysfunction in men after treatment for lower urinary tract symptoms: evidence from randomised controlled trial. BMJ, 2002: 324, 1059-1064 69. Netto NR Jr, De Lima ML, Lucena R, Lavoura NS, Cortado PL, Netto MR. Is transurethral vaporization a remake of transurethral resection of the prostate J Endourol, 1999: 13, 591-594 70. Erdagi U, Akman RY, Sargin SY, Yazicioglu A. Transurethral electrovaporization of the prostate versus transurethral resection of the prostate: a prospective randomized study. Arch Ital Urol Androl, 1999: 71, 125-130 71. Mcallister WJ, Karim O, Plail RO, Samra DR, Steggall MJ, Yang Q and Fowler CG. Transurethral electrovaporization of the prostate: is it any better than conventional transurethral resection of the prostate BJU Intern, 2003: 91, 211-214 72. Hammadeh MY, Madaan S, Singh M and Philp T. Two-year follow-up of a prospective randomised trial of electrovaporization versus resection of prostate. Eur Urol, 1998: 34, 188-192 73. Hammadeh MY, Madaan S, Singh M and Philp T. A 3-year follow-up of a prospective randomized trial comparing transurethral electrovaporization of the prostate with standard transurethral prostatectomy. BJU Intern, 2000: 86, 648-651 74. Hammadeh MY, Madaan S, Hines J and Philp T. 5-year outcome of a prospective randomized trial to compare transurethral electrovaporization of the prostate and standard transurethral resection. Urology, 2003: 61, 1166-1171 75. Abdel-Khalek M, El-Hammady S and Ibrahiem El-H. A 4-year follow-up of randomized prospective study comparing transurethral electrovaporization of the prostate with neodymium:YAG laser thgerapy for treating benign prostatic hyperplasia. BJU Intern, 2003: 91, 801-805 76. Roehrborn CG. Standard surgical interventions: TURP/TUIP/OPSU. In: Kirby R, Mc Connell J, Fitzpatrick J et al, editors. Textbook of benign prostatic hyperplasia. Oxford: ISIS <strong>Medica</strong>l Media, 1996, 341-378 77. Nouri M, Elkhadir K, el Fassi J, Koutani A, Ibn Attia A, Hachimi M, Lakrissa A. Benign prostatic hypertrophy: clinical and therapeutic aspects. Review of 1280 cases. Ann Urol, 1999: 33, 243-251 78. Gacci M, Bartoletti R, Figlioli S, Sarti E, Eisner B, Boddi V and Rizzo M. Urinary symptoms, quality of life and sexual function in patients with benign prostatic hypertrophy before and after prostatectomy: a prospective study. BJU Int, 2003 : 91, 196-200 250
- Page 2 and 3:
AURO.it Associazione Urologi Italia
- Page 4:
PRESENTAZIONE Carissimi, è la mia
- Page 7 and 8:
4. La Malattia IPB 77 4.1 Definizio
- Page 9 and 10:
5.10.3. Studio Pressione/Flusso 139
- Page 11 and 12:
6.4.1.3. Coagulazione laser interst
- Page 13 and 14:
8.1.2.4. Grado di specializzazione
- Page 16 and 17:
1.1. Perché una linea guida sull
- Page 18 and 19:
TAVOLA 1.1.2.-2: Evoluzione del num
- Page 20 and 21:
Scopo della Linea Guida La funzione
- Page 22 and 23:
1.3. Applicabilità Popolazione “
- Page 24 and 25:
1.4. Scelta della metodologia utili
- Page 26 and 27:
1.5. Dichiarazione di conflitto di
- Page 28 and 29:
15. Hassler E, Krakau I, haggarth L
- Page 30:
2 a. Evidenze scientifiche, Raccoma
- Page 33 and 34:
Forza delle Raccomandazioni Forte r
- Page 35 and 36:
VI VI III III III III III VI IV III
- Page 37 and 38:
La valutazione ecografica del volum
- Page 39 and 40:
Lo studio pressione/flusso dovrebbe
- Page 41 and 42:
Alfuzosina, Doxazosina, Tamsulosin
- Page 43 and 44:
Terapie mininvasive Laser TUMT TUNA
- Page 45 and 46:
Il laser a contatto o interstiziale
- Page 47 and 48:
TAVOLA 2a.-1. Algoritmo diagnostico
- Page 50:
2 b. Scientific evidence, Recommend
- Page 53 and 54:
Force of the Recommendations Strong
- Page 55 and 56:
VI VI III III III III III VI IV III
- Page 57 and 58:
Prostate volume should be measured
- Page 59 and 60:
Pressure-flow studies should be con
- Page 61 and 62:
Alfuzosin, Doxazosin, Tamsulosin an
- Page 63 and 64:
Minimally invasive therapy Laser TU
- Page 65 and 66:
Interstitial or contact laser may b
- Page 67 and 68:
TABLE 2b. -1. Diagnostical and ther
- Page 70:
3. Metodologia 57
- Page 73 and 74:
3.2. Summary of the methodology (En
- Page 75 and 76:
3.3. Scelta della Commissione Nella
- Page 77 and 78:
c) studio PRODEST (dati grezzi forn
- Page 79 and 80:
3.5. Graduazione (grading) delle ra
- Page 81 and 82:
3.6. Metodologia delle valutazioni
- Page 83 and 84:
TAVOLA 3.6.1. - 1. Ricerca bibliogr
- Page 85 and 86:
3.7. Indagine sulla pratica clinica
- Page 87 and 88:
3.8. Consensus Conference Anche la
- Page 89 and 90:
14. Vavassori I, Hurle R, Vismara A
- Page 92 and 93:
4.1. Definizione di Iperplasia Pros
- Page 94 and 95:
suggestive of lower urinary tract d
- Page 96 and 97:
iniziare che per mantenere o aument
- Page 98 and 99:
o altra evidente patologia. * Sinto
- Page 100 and 101:
4.2.4. Bibliografia 1. Rowan D, Jam
- Page 102 and 103:
4.3. Percezione dei sintomi La perc
- Page 104 and 105:
16. Tuncay Aki F, Aygun C, Bilir N,
- Page 106 and 107:
4.4. Evoluzione della IPB Attualmen
- Page 108 and 109:
III Età, severità dei sintomi, re
- Page 110:
22. McConnell JD, Roehrborn CG, Bau
- Page 113 and 114:
100
- Page 115 and 116:
5.1.2. Terapie concomitanti Lo stud
- Page 117 and 118:
III III * uso di farmaci * presenza
- Page 119 and 120:
5.2. Valutazione dei sintomi L’IP
- Page 121 and 122:
alcune domande dei symptom score (l
- Page 123 and 124:
12. Chatelain C, Denis L, Foo KT, K
- Page 125 and 126:
2. le dimensioni prostatiche; 3. le
- Page 127 and 128:
la calcolosi urinaria, il diabete m
- Page 129 and 130:
4. McConnell JD, Roehrborn CG, Baut
- Page 131 and 132:
Il PSA è indicato nella valutazion
- Page 133 and 134:
glienti rappresenta per il paziente
- Page 135 and 136:
vescicale è inferiore a 400 ml [11
- Page 137 and 138:
5.9. Imaging 5.9.1. Ecografia 5.9.1
- Page 139 and 140:
In assenza di prove scientifiche ce
- Page 141 and 142:
L’urografia endovenosa risulta su
- Page 143 and 144:
10. Smith RC, Rosenfield AT, Choe K
- Page 145 and 146:
5.10. Urodinamica 5.10.1. Diario Mi
- Page 147 and 148:
patologiche internistiche (ad es. m
- Page 149 and 150:
L’esame della curva flussimetrica
- Page 151 and 152:
5.10.2.1. Sintesi e raccomandazioni
- Page 153 and 154:
TAVOLA 5.10.3. - 1. Grafico dello s
- Page 155 and 156:
TAVOLA 5.10.3. - 3. Diagramma di Sc
- Page 157 and 158:
4. Hansen F.; Olsen L.; Atan A.; No
- Page 159 and 160:
32. Machino R; Kakizaki H; Ameda K;
- Page 161 and 162:
60. Netto NR. Jr.; de Lima ML.; Net
- Page 163 and 164:
L’uretrocistoscopia non è indica
- Page 165 and 166:
152
- Page 167 and 168:
3. C. Chatelain, L. Denis K. Foo, S
- Page 169 and 170:
Tutti gli α 1 -litici vengono somm
- Page 171 and 172:
I I Tamsulosin ed alfuzosina (nella
- Page 173 and 174:
23. Os I, Stokke HP. : Doxazosin GI
- Page 175 and 176:
TAVOLA 6.2.2. -1. Variazione media
- Page 177 and 178:
6.2.2.1.1.4. Volume prostatico La t
- Page 179 and 180:
3. Kirby RS, Roehrborn C, Boyle P,
- Page 181 and 182:
23. Andriole GL, Guess HA, Epstein
- Page 183 and 184:
internazionale sull’IPB tenutasi
- Page 185 and 186:
17. K. Dreikorn, A. Borkowski, C. B
- Page 187 and 188:
TAVOLA 6.2.4- 2. Variazioni medie d
- Page 189 and 190:
2. Lepor H, Williford WO, Barry MJ,
- Page 191 and 192:
TAVOLA 6.2.5. -1. Costi (EURO) del
- Page 193 and 194:
11. Chirikos TN, Sanford E. Cost co
- Page 195 and 196:
delle seguenti condizioni patologic
- Page 197 and 198:
necessario prolungare il follow up
- Page 199 and 200:
l’incidenza di emorragia intraope
- Page 201 and 202:
III IV L’adenomectomia a cielo ap
- Page 203 and 204:
19. Tubaro A., Vicentini C., Renzet
- Page 205 and 206:
47. Concato J., Horwitz R.I., Feins
- Page 207 and 208:
6.3.3.2. Risultati, complicanze, du
- Page 209 and 210:
14. Bukala B, Denstedt JD. : Holmiu
- Page 211 and 212: 6.4. Terapie Mininvasive Dovrebbero
- Page 213 and 214: una procedura più sicura rispetto
- Page 215 and 216: V III III III III V Il laser side f
- Page 217 and 218: of endoscopic laser ablation agains
- Page 219 and 220: temperatura intraprostatica real- t
- Page 221 and 222: isogna specificare che in questi st
- Page 223 and 224: morfologia degli spermatozoi [19].
- Page 225 and 226: 212 6. Djavan B, Seitz C, Roehrborn
- Page 227 and 228: dalla ditta produttrice, questo ren
- Page 229 and 230: manente della loro attività. Ecco
- Page 231 and 232: dovrebbe comprendere la visita e la
- Page 233 and 234: vescica per l’alto numero di disl
- Page 235 and 236: VI VI Le casistiche relative alla W
- Page 237 and 238: 6.4.5.1. Bibliografia 1. Ackerman S
- Page 239 and 240: 226
- Page 241 and 242: 7.1.2. Sistemi di valutazione della
- Page 243 and 244: OLMSTED COUNTY STUDY [15-18]. Quest
- Page 245 and 246: popolazione studiata, la frequenza
- Page 247 and 248: 7.2 Influenza delle terapie per IPB
- Page 249 and 250: 7.2.1.1.4. TAMSULOSIN Svariati tria
- Page 251 and 252: nenti 3 anni di studio, l’inciden
- Page 253 and 254: eventi avversi e la percentuale di
- Page 255 and 256: sessuale a seconda delle differenze
- Page 257 and 258: III III La disfunzione ejaculatoria
- Page 259 and 260: 14. Leliefeld HHJ, Stoevelaar HJ an
- Page 261: 42. Roehrborn CG, van Kerrebroek P
- Page 265 and 266: 252
- Page 267 and 268: 8.1.1. Passaggi per l’implementaz
- Page 269 and 270: nisti delle Direzioni Sanitarie che
- Page 271 and 272: se rallenta un iter diagnostico-ter
- Page 273 and 274: grado di raggiungere la popolazione
- Page 275 and 276: 262
- Page 277 and 278: Tavoni Francesca Geriatra UO Geriat
- Page 279 and 280: 9.2. Protocollo delle review 1) Def
- Page 281 and 282: 9.3. Quesiti scientifici delle revi
- Page 283 and 284: Titolo Scopo Quesito PSA Quando dos
- Page 285 and 286: Titolo Scopo Quesito Endoscopia Qua
- Page 287 and 288: Titolo Scopo Quesito Terapie altern
- Page 289 and 290: Titolo Scopo Quesito IPB e sessuali
- Page 291 and 292: 9.4. Diagramma di selezione dei lav
- Page 293 and 294: . Evoluzione IPB, Fattori di Progre
- Page 295 and 296: f. Terapia Medica 1. α-1 litici La
- Page 297 and 298: g. Terapie Chirurgiche DATI GENERIC
- Page 299 and 300: i. IPB e Sessualità //////////////
- Page 301 and 302: k. Terapia Chirurgica e Sessualita
- Page 303 and 304: 9.6. Fasi della valutazione economi
- Page 305 and 306: 9.7. Elenco dei questionari pervenu
- Page 307 and 308: 294 96. PATTACINI PIERPAOLO RADIOLO
- Page 309 and 310: 296 200. MARTINENGO CARLO UROLOGO 2
- Page 311 and 312: 9.8. Risultati del Questionario Com
- Page 313 and 314:
300 GRUPPI ZONE CAMPIONE UROLOGI UR
- Page 315 and 316:
302 GRUPPI ZONE CAMPIONE UROLOGI UR
- Page 317 and 318:
304 GRUPPI ZONE CAMPIONE UROLOGI UR
- Page 319 and 320:
Per ogni opzione terapeutica indica
- Page 321 and 322:
2 3 308
- Page 323 and 324:
6 7 310
- Page 325 and 326:
10 11 312
- Page 327 and 328:
14 15 314
- Page 329 and 330:
18 19 316